2-Methyl-4-(methylthio)butanoic acid | 122665-98-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Methyl-4-(methylthio)butanoic acid
• 英文别名: 2-methyl-4-methylsulfanylbutanoic acid
• CAS: 122665-98-9
• 化学式: C₆H₁₂O₂S
• 分子量: 148.23
• InChiKey: QSCMVGTXPXZIOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• COMPOUNDS FROM ANTRODIA CINNAMOMEA AND USE THEREOF
  申请人：SIMPSON BIOTECH CO., LTD.

  公开号：US20130225649A1

  公开（公告）日：2013-08-29

  The present invention relates to compounds from Antrodia cinnamomea . The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection.

  本发明涉及来自红树菇的化合物。本发明还涉及一种用于治疗或预防丙型肝炎病毒（HCV）或人类免疫缺陷病毒（HIV）感染的组合物和方法。
• QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT
  申请人：Wang Shulong

  公开号：US20150080392A1

  公开（公告）日：2015-03-19

  A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.

  提供一类具有新颖结构的喹唑啉衍生物或其药用可接受的盐或溶剂；同时，还提供了一种包含所述喹唑啉衍生物或其药用可接受的盐或溶剂的药物组合物，以及药用可接受的赋形剂或添加剂。通过修改和转化喹唑啉，并对转化后的化合物在酪氨酸激酶抑制活性上的筛选，发现大多数化合物对EGFR、VEGFR-2、c-erbB-2、c-erbB-4、c-met、tie-2、PDGFR、c-src、lck、Zap70和fyn激酶中的一个或几个具有抑制活性。本发明具有设计合理、原料来源广泛且易获得、制备方法简单易行、反应条件温和、产品产率高且有利于工业规模生产的优点。
• HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20150231268A1

  公开（公告）日：2015-08-20

  The present invention provides a hyaluronic acid derivative containing a disaccharide unit represented by formula (I) or formula (I) and (II), and a complex containing the hyaluronic acid derivative and a drug.

  本发明提供了一种含有由化学式（I）或化学式（I）和（II）表示的二糖单元的透明质酸衍生物，以及含有该透明质酸衍生物和药物的复合物。
• PROCESS FOR MANUFACTURING EXTREMELY PURE BENZAZEPINE DERIVATIVES
  申请人：GERDES Klaus

  公开号：US20090326219A1

  公开（公告）日：2009-12-31

  A process for the production of extremely pure galanthamine or extremely pure galanthamine derivatives, a start is made from racemic bromine narwedine, which is debrominated under palladium catalysis. In this case, the working-up of the reaction mixture, which is carried out in the presence of oxygen or peroxides so that the palladium catalyst in an insoluble form is converted into an easily separable form, is essential. The further reaction is carried out by reduction of enantiomer-pure narwedine to form enantiomer-pure galanthamine, whereby it is then alkylated or dealkylated so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved, so that direct use as a pharmaceutical raw material is made possible.

  一种生产极纯的风信子碱或其衍生物的方法，首先从外消旋溴化纳尔维丁开始，通过钯催化去溴化。在这种情况下，反应混合物的处理必须在氧气或过氧化物的存在下进行，以便将钯催化剂转化为易于分离的不溶形式。进一步的反应是将对映纯的纳尔维丁还原成对映纯的风信子碱，然后通过烷基化或去烷基化使环氮原子上发生相应的取代。通过进一步的纯化，如重结晶，可以实现钯的残留量低于5 ppm，从而使其可以直接用作药用原料。
• Corrosion Inhibitors Having Increased Biodegradability and Reduced Toxicity
  申请人：Leinweber Dirk

  公开号：US20100234592A1

  公开（公告）日：2010-09-16

  The invention relates to the use of salts of compounds of the formula (1) and amines of the formula (2) where R 1 is C 1 - to C 30 -alkyl, C 2 - to C 30 -alkenyl, C 6 - to C 30 -aryl or C 7 - to C 30 -alkylaryl, R 2 is C 1 - to C 30 -alkyl, C 2 - to C 30 -alkenyl, C 6 - to C 30 -aryl or C 7 - to C 30 -alkylaryl, or an optionally heteroatom containing organic radical having from 1 to 30 carbon atoms, and R 3 and R 4 are each independently hydrogen, C 1 - to C 30 -alkyl, C 2 - to C 30 -alkenyl, C 6 - to C 30 -aryl or C 7 - to C 30 -alkylaryl, or an optionally heteroatom containing organic radical having from 1 to 30 carbon atoms, where R 3 and R 4 can also form, with the inclusion of the nitrogen atom, a ring having from 5 to 7 ring atoms.

  本发明涉及使用公式（1）化合物的盐和公式（2）胺的用途，其中R1为C1-至C30-烷基，C2-至C30-烯基，C6-至C30-芳基或C7-至C30-烷基芳基，R2为C1-至C30-烷基，C2-至C30-烯基，C6-至C30-芳基或C7-至C30-烷基芳基，或具有1至30个碳原子的可选择含杂原子的有机基团，R3和R4各自独立地为氢，C1-至C30-烷基，C2-至C30-烯基，C6-至C30-芳基或C7-至C30-烷基芳基，或具有1至30个碳原子的可选择含杂原子的有机基团，其中R3和R4还可以与氮原子一起形成具有5至7个环原子的环。